501 Elliott Avenue West
Suite 400
Seattle, Washington 98119
United States
Telephone
206-282-7100
Fax
206-284-6206
CERTIFICATIONS & ACCREDITATIONS
COMPANY EXECUTIVES
Bianco, James A. (Board); Philips, Craig W.; Bianco, Louis A.; Singer, Jack W. (Board); Bernareggi, Alberto; Leigh, Richard E.; Spinelli, Silvano (Prior Board); Wyatt, Donald W.; Eramian, Dan; Comis, Silvia
BOARD MEMBERS
Nudelman, Phillip M. (Board); Bianco, James A. (Board); Singer, Jack W. (Board); Bauer, John H. (Board); Gregorian, Vartan (Board); Telling, Frederick W. (Board); Love, Richard L. (Board); Mundinger, Mary O'Neil (Board)
COMPETITORS
Roche Holding AG (SWX:ROG); Sanofi-Aventis (ENXTPA:SAN); PharmaMar USA, Inc.; Sonus Pharmaceuticals Inc.; Genta Incorporated (OTCBB:GETA); Arius Research Inc.; Bristol-Myers Squibb Co. (NYSE:BMY); Merck Serono S.A.; Genmab A/S (CPSE:GEN); Telik Inc. (NasdaqGM:TELK); Genentech, Inc.; Genitope Corp. (OTCPK:GTOP); Wyeth (NYSE:WYE); OSI Pharmaceuticals Inc. (NasdaqGS:OSIP); Abraxis BioScience, Inc. (NasdaqGS:ABII); Cephalon Inc. (NasdaqGS:CEPH); Millennium Pharmaceuticals, Inc.; TEVA Pharmaceuticals USA, Inc.; Kyto BioPharma Inc. (OTCBB:KBPH); Celgene Corporation (NasdaqGS:CELG); GlaxoSmithKline plc (LSE:GSK); Oxigene Inc. (NasdaqGM:OXGN); Supratek Pharma Inc.; Chemokine Therapeutics Corp. (TSX:CTI); Eli Lilly & Co. (NYSE:LLY); Arrowhead Research Corp. (NasdaqCM:ARWR); Aventis S.A.; Biovest International Inc. (OTCPK:BVTI); Evivrus, Inc.; Acusphere Inc. (OTCPK:ACUS); Fresenius Kabi Pharmaceuticals Holding, Inc.; NeoPharm, Inc. (OTCPK:NEOL); Favrille Inc.
Cell Therapeutics, Inc.
Cell Therapeutics, Inc., a biopharmaceutical company, develops, acquires, and commercializes oncology products for cancer treatment. Its development portfolio includes Pixantrone, a phase III trial product, for non-Hodgkin’s lymphoma; Brostallicin, which is in first-line Phase II study for the treatment of sarcoma; and OPAXIO, a chemotherapeutic agent for the potential treatment of non-small cell lung, ovarian, and other cancers. It has collaboration and licensing arrangements with Novartis International Pharmaceutical, Ltd.; and PG-TXL Company, L.P. The company was founded in 1991 and is headquartered in Seattle, Washington.
